Drug intelligence / Profile preview

C-103

Development stage: Preclinical
Lead developer: Callitas Therapeutics
Modality: Small Molecules

Overview

C-103 is an investigational drug developed by M Pharmaceutical, which acquired it from Chelatexx, LLC. It is a reformulated version of orlistat, a weight-loss drug. C-103 functions as a lipase inhibitor, preventing the absorption of dietary fats and is intended for obesity and weight management.

Targets

LIPF (Gastric lipase)PNLIP (Pancreatic triacylglycerol lipase)

Beyond the preview

Go deeper on C-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-103.

Explore the full profile